Cargando…

Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression

BACKGROUND: As cell-free circulating DNA exists predominantly as mono- and oligonucleosomes, the focus of the current study was to examine the interplay of circulating nucleosomes, DNA, proteases and caspases in blood of patients with benign and malignant breast diseases. METHODS: The concentrations...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roth, Carina, Pantel, Klaus, Müller, Volkmar, Rack, Brigitte, Kasimir-Bauer, Sabine, Janni, Wolfgang, Schwarzenbach, Heidi
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024991/ https://www.ncbi.nlm.nih.gov/pubmed/21211028 http://dx.doi.org/10.1186/1471-2407-11-4

Ejemplares similares

Circulating microRNAs: promising breast cancer biomarkers - authors' response
por: Roth, Carina, et al.
Publicado: (2011)

Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer
por: Roth, Carina, et al.
Publicado: (2010)

Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study
por: Müller, Volkmar, et al.
Publicado: (2012)

Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer
por: Müller, Volkmar, et al.
Publicado: (2011)

Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients
por: Stückrath, Isabel, et al.
Publicado: (2015)

Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2017)

Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients
por: Aktas, Bahriye, et al.
Publicado: (2016)

Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2018)

The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2019)

Circulating DNA as biomarker in breast cancer
por: Schwarzenbach, Heidi, et al.
Publicado: (2015)

Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer
por: Schwarzenbach, Heidi, et al.
Publicado: (2009)

Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer
por: Meng, Xiaodan, et al.
Publicado: (2016)

Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients
por: Eichelser, Corinna, et al.
Publicado: (2014)

Low Levels of Cell-Free Circulating miR-361-3p and miR-625* as Blood-Based Markers for Discriminating Malignant from Benign Lung Tumors
por: Roth, Carina, et al.
Publicado: (2012)

Interplay of lncRNA H19/miR‐675 and lncRNA NEAT1/miR‐204 in breast cancer
por: Müller, Volkmar, et al.
Publicado: (2019)

LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival
por: Kuhlmann, Jan Dominik, et al.
Publicado: (2012)

A critical evaluation of loss of heterozygosity detected in tumor tissues, blood serum and bone marrow plasma from patients with breast cancer
por: Schwarzenbach, Heidi, et al.
Publicado: (2007)

Bone marrow micrometastases and circulating tumor cells: current aspects and future perspectives
por: Müller, Volkmar, et al.
Publicado: (2004)

Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients
por: Ni, Qingtao, et al.
Publicado: (2018)

Exosomal microRNAs as tumor markers in epithelial ovarian cancer
por: Pan, Chi, et al.
Publicado: (2018)

Author Correction: Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients
por: Ni, Qingtao, et al.
Publicado: (2019)

Promoter- and cell-specific epigenetic regulation of CD44, Cyclin D2, GLIPR1 and PTEN by Methyl-CpG binding proteins and histone modifications
por: Müller, Imke, et al.
Publicado: (2010)

Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma – What is the Role of Liquid Biopsy in Breast Cancer?
por: Polasik, Arkadius, et al.
Publicado: (2017)

Recent translational research: circulating tumor cells in breast cancer patients
por: Müller, Volkmar, et al.
Publicado: (2006)

Angiogenic cytokines and their influence on circulating tumour cells in sera of patients with the primary diagnosis of breast cancer before treatment
por: Vilsmaier, Theresa, et al.
Publicado: (2016)

Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients
por: Meng, Xiaodan, et al.
Publicado: (2015)

Circulating Mitochondrial DNA is Linked to Progression and Prognosis of Epithelial Ovarian Cancer
por: Meng, Xiaodan, et al.
Publicado: (2019)

Circulating Tumor Cells in Breast Cancer Patients: A Balancing Act between Stemness, EMT Features and DNA Damage Responses
por: Heitmeir, Benedikt, et al.
Publicado: (2022)

53BP1 Accumulation in Circulating Tumor Cells Identifies Chemotherapy-Responsive Metastatic Breast Cancer Patients
por: Schochter, Fabienne, et al.
Publicado: (2020)

Circulating nucleic acids as biomarkers in breast cancer
por: Schwarzenbach, Heidi
Publicado: (2013)

Circulating Nucleosomes and Nucleosome Modifications as Biomarkers in Cancer
por: McAnena, Peter, et al.
Publicado: (2017)

Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients
por: Rack, Brigitte, et al.
Publicado: (2014)

Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases
por: Joosse, S A, et al.
Publicado: (2014)

Detection and Characterization of Estrogen Receptor α Expression of Circulating Tumor Cells as a Prognostic Marker
por: Ningsi, Retno, et al.
Publicado: (2022)

Heterogeneity of Estrogen Receptor Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients
por: Babayan, Anna, et al.
Publicado: (2013)

Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: a prospective study
por: Soave, Armin, et al.
Publicado: (2017)

Are Circulating Tumor Cells (CTCs) Ready for Clinical Use in Breast Cancer? An Overview of Completed and Ongoing Trials Using CTCs for Clinical Treatment Decisions
por: Schochter, Fabienne, et al.
Publicado: (2019)

The current role of circulating biomarkers in non-muscle invasive bladder cancer
por: Rink, Michael, et al.
Publicado: (2019)

Association of Soluble B7-H4 and Circulating Tumor Cells in Blood of Advanced Epithelial Ovarian Cancer Patients
por: Mach, Pawel, et al.
Publicado: (2021)

Circulating non-coding RNAs in recurrent and metastatic ovarian cancer
por: Schwarzenbach, Heidi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_377cs259f4acp3b40hjsm8ij8i